

Date: 11th February, 2022

To,
BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001.
Scrip Code: 511523

Sub.: Unaudited Financial Results for the quarter and nine months ended December 31, 2021


Dear Sir,

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

1. Statement showing the Unaudited Financial Results for the quarter and nine months ended December 31, 2021.
2. Limited Review Report on the Unaudited Financial Results for the quarter and nine months ended December 31, 2021.

Thanking You.

Yours faithfully,
For Veerhealth Care Limited



Bhavin S. Shah
Managing Director
DIN: 03129574



Encl: As above

VEERHEALTH CARE LIMITED

Regd Office: 629-A, Gazdar House, 1st Floor, J.S.S. Marg, Near Kalbadevi Post Office, Mumbai - 400002.

Tel. No. 022-22018582 Fax. No. 022-22072644 CIN: L65910MH1992PLC067632

Email: info@veerhealthcare.net Website: www.veerhealthcare.net

Statement of Unaudited Financial Results for the Quarter and Nine months ended December 31, 2021

(Rs. in lakhs)

Sr. No.	Particulars	Standalone					
		Quarter ended 31-12-2021	Quarter ended 30-09-2021	Quarter ended 31-12-2020	Nine Months ended 31-12-2021	Nine Months ended 31-12-2020	Year ended 31-03-2021
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from operations	264.96	247.44	385.25	761.15	869.57	1057.98
II	Other Income	44.01	36.77	29.99	104.07	58.80	119.67
III	Total Revenue (I + II)	308.97	284.21	415.24	865.22	928.37	1177.65
IV	Expenses:						
	(a) Cost of materials consumed	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Purchase of stock-in-trade	157.76	144.10	259.60	522.89	631.01	794.88
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	40.42	39.39	24.58	30.78	-19.71	-43.27
	(d) Employee benefits expense	23.54	17.41	17.91	57.84	52.28	83.10
	(e) Finance Costs	0.08	1.25	5.33	4.68	16.17	21.85
	(f) Depreciation and amortisation expense	13.30	13.13	11.79	39.04	34.90	46.82
	(g) Other expenses	55.12	65.37	78.81	181.82	139.64	216.61
	Total Expenses	290.22	280.65	398.02	837.05	854.29	1119.99
V	Profit/(Loss) before exceptional items (III - IV)	18.75	3.56	17.22	28.17	74.08	57.66
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
VII	Profit before tax (V - VI)	18.75	3.56	17.22	28.17	74.08	57.66
VIII	Tax expense:						
	1) Current Tax	1.60	0.52	7.00	3.00	16.00	9.49
	2) Prior Year Tax	0.00	0.00	0.00	0.00	0.00	5.63
	3) Deferred Tax	0.00	0.00	0.00	0.00	0.00	4.63
IX	Profit/(Loss) for the period (VII - VIII)	17.15	3.04	10.22	25.17	58.08	37.91
X	Other Comprehensive Income						
	(a) Items that will not be reclassified to Profit or Loss	-2.43	-2.43	0.55	-7.28	1.66	-9.24
	(b) Income Tax effect on above	0.00	0.00	0.00	0.00	0.00	0.00
	Other Comprehensive Income	-2.43	-2.43	0.55	-7.28	1.66	-9.24
XI	Total Comprehensive Income for the period (IX + X)	14.72	0.61	10.77	17.89	59.74	28.67
XII	Paid-up equity share capital of Rs. 10 each	693.42	693.42	693.42	693.42	693.42	693.42
XIII	Other Equity						710.89
XIV	Net Worth						1404.31
XV	Earnings Per Share (of Rs. 10 each):						
	(a) Basic (in Rs.)	0.25	0.04	0.15	0.36	0.84	0.55
	(b) Diluted (in Rs.)	0.25	0.04	0.15	0.36	0.84	0.55

TranSgess



VEERHEALTH CARE LIMITED

Regd Office: 629-A, Gazdar House, 1st Floor, J.S.S. Marg, Near Kalbadevi Post Office, Mumbai - 400002.

Tel. No. 022-22018582 Fax. No. 022-22072644 CIN: L65910MH1992PLC067632

Email: info@veerhealthcare.net Website: www.veerhealthcare.net

NOTES:

- 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 11th February, 2022. The Limited Review under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been carried out by the Statutory Auditors. The limited review report does not contain any observation which would have an impact on the above results.
- 2 The standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ('IND AS') prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and guidelines issued by the Securities and Exchange Board of India ("SEBI").
- 3 The spread of COVID-19 has severely impacted business around the globe. In many countries including India, there has been severe disruption to regular business operations due to lock-down, disruptions in transportation, supply chain, travel bans, quarantines, social distancing and other emergency measures. The Company has made detailed assessment of its liquidity position for the next one year and has concluded that there is no material adjustments required in the financial results for the quarter ended December 31, 2021. Management believes that it has considered all the possible impact of known events arising from COVID-19 pandemic in the preparation of the financial results for the quarter ended December 31, 2021. However, the impact assessment of COVID-19 is a continuing process given the uncertainties associated with its nature and duration. The Company will continue to monitor any material changes to future economic conditions.
- 4 During the quarter ended December 31, 2021 the Company is operating in a single segment i.e. "'Ayurved Pharma Products'. Accordingly, segment wise reporting is not applicable.
- 5 Figures of the previous periods have been regrouped, wherever necessary.
- 6 The financial results of the Company are available at www.bseindia.com, at www.msei.in and at www.veerhealthcare.net.

Place: Mumbai
Date: 11th February, 2022



By order of the Board
For Veerhealth Care Limited

Bhavin S. Shah
Managing Director
DIN: 03129574



Limited Review Report

Review Report to the Board of Directors of Veerhealth Care Limited

We have reviewed the accompanying statement of unaudited financial results of M/s. Veerhealth Care Limited ("the Company") for the quarter and nine months ended December 31, 2021. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an Audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

For M. H. Dalal & Associates
Chartered Accountants
FRN: 112449W

Devang M. Dalal
Partner
M. No. 109049
UDIN: 22109049ABJYRJ6981
Place: Mumbai
Date: 11th February, 2022

